Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX-102 for Gastrointestinal Symptoms in Naïve Fabry Disease
NCT02921620Phase 3Withdrawn
- Sponsor
- Protalix BioTherapeutics
- Start
- Jul 2017
- Primary completion
- Jul 2018
- Modality
- PEGylated Peptides, Replacement Enzymes
01
Overview
Phase 3, randomised, double-blind trial in Fabry disease (FD) comparing PRX-102 with Placebo (2 arms). Primary endpoint: Irritable Bowel Symptom Severity Score Part 1. Planned start Jul 2017; status: withdrawn.
02
Drugs
pegunigalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT02921620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02921620.